Spots Global Cancer Trial Database for A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma
Official Title: A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma
Study ID: NCT06308575
Interventions
Study Description
Brief Summary: To learn if rivoceranib can help to control olfactory neuroblastoma. The safety of this drug in participants with olfactory neuroblastoma will also be studied.
Detailed Description: Primary Objective: - To assess the efficacy of rivoceranib in patients with R/M ONB Secondary Objective: * To estimate the median duration of response (DOR) * Time to response * To estimate the median progression-free survival (PFS) * To estimate the median overall survival (OS) * To assess safety of rivoceranib Tertiary Objective: - To explore biomarkers that may predict response to therapy
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: Yes
Locations
MD Anderson Cancer Center, Houston, Texas, United States
Contact Details
Name: Luana Guimaraes De Sousa, MD
Affiliation: M.D. Anderson Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
